EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children

Mingyao Sun, Honghao Lai, Feiyang Na, Sheng Li, Xia Qiu, Jinhui Tian, Zhigang Zhang, Long Ge

JAMA Network Open · 17.02.2023 · 6 (2) · e230023

DOI: 10.1001/jamanetworkopen.2023.0023 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Network Open, online erschienen am 17.02.2023. Verfasst von Mingyao Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, The First Hospital of Lanzhou University, Lanzhou, Gansu, China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Tract Infections. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infection in children younger than 5 years; effective prevention strategies are urgently needed.

Objective

To compare the efficacy and safety of monoclonal antibodies for the prevention of RSV infection in infants and children. Data Sources In this systematic review and network meta-analysis, PubMed, Embase, CENTRAL, and ClinicalTrials.gov were searched from database inception to March 2022. Study Selection Randomized clinical trials that enrolled infants at high risk of RSV infection to receive a monoclonal antibody or placebo were included. Keywords and extensive vocabulary related to monoclonal antibodies, RSV, and randomized clinical trials were searched. Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was used. Teams of 2 reviewers independently performed literature screening, data extraction, and risk of bias assessment. The Grading of Recommendations, Assessments, Developments, and Evaluation approach was used to rate the certainty of evidence. A random-effects model network meta-analysis was conducted using a consistency model under the frequentist framework. Main Outcomes and Measures The main outcomes were all-cause mortality, RSV-related hospitalization, RSV-related infection, drug-related adverse events, intensive care unit admission, supplemental oxygen use, and mechanical ventilation use.

Results

Fifteen randomized clinical trials involving 18 395 participants were eligible; 14 were synthesized, with 18 042 total participants (median age at study entry, 3.99 months [IQR, 3.25-6.58 months]; median proportion of males, 52.37% [IQR, 50.49%-53.85%]). Compared with placebo, with moderate- to high-certainty evidence, nirsevimab, palivizumab, and motavizumab were associated with significantly reduced RSV-related infections per 1000 participants (nirsevimab: −123 [95% CI, −138 to −100]; palivizumab: −108 [95% CI, −127 to −82]; motavizumab: −136 [95% CI, −146 to −125]) and RSV-related hospitalizations per 1000 participants (nirsevimab: −54 [95% CI, −64 to −38; palivizumab: −39 [95% CI, −48 to −28]; motavizumab: −48 [95% CI, −58 to −33]). With moderate-certainty evidence, both motavizumab and palivizumab were associated with significant reductions in intensive care unit admissions per 1000 participants (−8 [95% CI, −9 to −4] and −5 [95% CI, −7 to 0], respectively) and supplemental oxygen use per 1000 participants (−59 [95% CI, −63 to −54] and −55 [95% CI, −61 to −41], respectively), and nirsevimab was associated with significantly reduced supplemental oxygen use per 1000 participants (−59 [95% CI, −65 to −40]). No significant differences were found in all-cause mortality and drug-related adverse events. Suptavumab did not show any significant benefits for the outcomes of interest. Conclusions and Relevance In this study, motavizumab, nirsevimab, and palivizumab were associated with substantial benefits in the prevention of RSV infection, without a significant increase in adverse events compared with placebo. However, more research is needed to confirm the present conclusions, especially for safety and cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Tract InfectionsMaleInfantChildHumansAntibodies, MonoclonalPalivizumabRespiratory Syncytial VirusesOxygenRandomized Controlled Trials as Topic

Substanzen

Antibodies, MonoclonalPalivizumabOxygen

Autor:innen und Institutionen

  • Department of Intensive Care Unit, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
  • Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou, Gansu, China.
  • Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China.
  • Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, Gansu, China.
  • Department of Pediatrics, Gansu Provincial Maternity and Child Care Hospital, Lanzhou, Gansu, China.
  • The First People's Hospital of Lanzhou City, Lanzhou, Gansu, China.

Zitieren

APA

Sun, M., Lai, H., Na, F., Li, S., Qiu, X., Tian, J., Zhang, Z., & Ge, L. (2023). Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children. JAMA Network Open, 6(2), e230023. https://doi.org/10.1001/jamanetworkopen.2023.0023

Vancouver

Sun M, Lai H, Na F, Li S, Qiu X, Tian J, et al. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children. JAMA Network Open. 2023;6(2):e230023. doi:10.1001/jamanetworkopen.2023.0023

BibTeX
@article{Sun2023,
  author = {Sun, Mingyao and Lai, Honghao and Na, Feiyang and Li, Sheng and Qiu, Xia and Tian, Jinhui and Zhang, Zhigang and Ge, Long},
  title = {Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {e230023},
  doi = {10.1001/jamanetworkopen.2023.0023}
}
Kostenlos starten →